文献速递神经肿瘤

胶质瘤患者的质量调整生命年:现有数据系统综述及基于证据的效用值缺乏

Quality-adjusted life years in glioma patients: a systematic review on currently available data and the lack of evidence-based utilities.
PubMed 文献 · J Neurooncol · 2019-06-12

该系统综述检索Medline和Cochrane Library,纳入29项研究(1995-2018),分析胶质瘤患者健康经济学评价。仅16项研究使用QALY作为结局指标,多数使用总生存期或生命年获得(LYG);效用值或基于单一研究或源自视觉模拟量表(VAS),无研究评估特定健康状态的效用值。增量成本效果比从每QALY 8325€(5-ALA)到每LYG 518,342€(肿瘤治疗电场)不等。结论指出健康经济学评价缺乏特定效用值,需进一步研究以在神经外科背景下进行可靠的成本效果分析(CEA)。

要点

  • 胶质瘤健康经济学评价中仅16/29项研究使用QALY作为结局指标。
  • 效用值多基于单一研究或VAS,无研究评估特定健康状态效用值。
  • 增量成本效果比范围从每QALY 8325€(5-ALA)到每LYG 518,342€(肿瘤治疗电场)。

核心结论

  • 仅一项研究生成效用值以进行成本效果分析(CEA),多数研究使用LYG等间接结局或基于已发表数据建模。
  • 健康经济学评价缺乏特定效用值,需进一步研究以在神经外科背景下进行可靠的CEA。

研究设计与样本

  • 系统数据库检索包括Medline和Cochrane Library。
  • 共识别37项研究(1995-2018),29项符合纳入标准。
  • 研究证据根据牛津循证医学中心治疗性研究证据级别进行分类。

主要发现

  • 研究涉及手术成本效益和/或标准治疗、术后化疗(n=6)和5-ALA(n=3)。
  • 仅16项研究使用QALY作为结局指标,多数使用总生存期或生命年获得(LYG)。
  • 效用值或基于单一研究(Garside等,Health Technol Assess 11:iii-iv, ix-221)或源自视觉模拟量表(VAS)。
  • 增量成本效果比从每QALY 8325€(5-ALA)到每LYG 518,342€(肿瘤治疗电场)不等。

局限性

  • 健康经济学评价缺乏特定效用值,多数研究使用间接结局或基于已发表数据建模。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cost-effectiveness studies gain importance in the context of rising health care expenses and treatment options. Especially in the neuro-oncological context, surgical therapy may increase overall survival, but restrain the patient by postoperative disability. Quality-adjusted life years, express treatment effects and are based on health utilities. In our study, we analyze the current evidence on health economic evaluations in glioma patients. MATERIAL AND METHODS: We performed a systematic database search including Medline and Cochrane Library. Studies were critically appraised for statistical analyzes including glioma patients, health economic modeling and detailed health outcome. Study evidence was classified according to levels of evidence for therapeutic studies from the Centre for Evidence-Based Medicine (Oxford). RESULTS: 37 studies (1995-2018) were identified, 29 matched our inclusion criteria. Studies addressed surgical cost-efficiency and/or the standard treatment, postoperative chemotherapy (n = 6) and 5-ALA (n = 3). Only 16 studies used QALY as the outcome measure, most used overall survival or life years gained (LYG). Utilities were either based on one single study (Garside et al. in Health Technol Assess 11:iii-iv, ix-221) or derived from visual analogue scale (VAS). None assessed quality of life values for specific health statuses or utilities. Incremental cost-effectiveness ratios varied from 8325€ per QALY (5-ALA) to 518,342€ per LYG (tumor treating fields). CONCLUSIONS: Only one study generated utility values to conduct cost-effectiveness analysis (CEA); most studies used indirect outcomes such as LYG or based their model on previously published data. Health economic evaluations lack specific utilities, further investigations are necessary to conduct reliable CEA in the neurosurgical context.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Butenschoen VM, Kelm A, Meyer B, et al. Quality-adjusted life years in glioma patients: a systematic review on currently available data and the lack of evidence-based utilities. J Neurooncol. 2019. PMID: 31187319. doi:10.1007/s11060-019-03210-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。